Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Express Scripts
Fuji
Boehringer Ingelheim
Dow
McKesson
Chinese Patent Office
Novartis
Merck
Johnson and Johnson

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,642,538

« Back to Dashboard

Which drugs does patent 8,642,538 protect, and when does it expire?


Patent 8,642,538 protects VIEKIRA PAK (COPACKAGED), VIEKIRA XR, and TECHNIVIE, and is included in three NDAs.

This patent has eighty-two patent family members in thirty-seven countries.

Summary for Patent: 8,642,538

Title:Macrocyclic hepatitis C serine protease inhibitors
Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Inventor(s): Ku; Yiyin (Buffalo Grove, IL), McDaniel; Keith F. (Wauconda, IL), Chen; Hui-Ju (Grayslake, IL), Shanley; Jason P. (Chicago, IL), Kempf; Dale J. (Libertyville, IL), Grampovnik; David J. (Waukegan, IL)
Assignee: AbbVie, Inc. (North Chicago, IL)
Application Number:13/439,551
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeYY TREATMENT OF HCV INFECTION USING PARITAPREVIR
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeYY TREATMENT OF HCV INFECTION USING PARITAPREVIR
Abbvie Inc
TECHNIVIE
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► SubscribeYY TREATMENT OF HCV INFECTION USING PARITAPREVIR
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,642,538

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,332,661Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices► Subscribe
9,043,925Method and apparatus for prevention of tampering and unauthorized extraction of information from microdevices► Subscribe
9,309,279Macrocyclic hepatitis C serine protease inhibitors► Subscribe
8,420,596Macrocyclic hepatitis C serine protease inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,642,538

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina073568► Subscribe
Argentina086181► Subscribe
Argentina093924► Subscribe
Australia2009292182► Subscribe
Brazil122012005261► Subscribe
BrazilPI0918724► Subscribe
Canada2736895► Subscribe
China101775017► Subscribe
China102641271► Subscribe
China103896950► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Citi
Mallinckrodt
Covington
Merck
Novartis
Dow
Chinese Patent Office
Julphar
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot